Key insights
- Quantum BioPharma (QNTM) announced positive clinical trial results for its alcohol metabolism supplement, unbuzzd, showing a faster reduction in blood alcohol concentration compared to placebo. While the stock has struggled recently, InvestingPro analysis suggests it may be undervalued. The news could provide a short-term boost to the stock, but the long-term impact on US equities is minimal.
TORONTO - Quantum BioPharma Ltd. (NASDAQ:QNTM) announced today the peer-reviewed publication of a clinical trial examining its dietary supplement unbuzzd, designed to affect alcohol metabolism and intoxication symptoms.
The double-blind, randomized, placebo-controlled crossover study was published in the World Journal of Pharmaceutical and Medical Research. The trial included healthy participants aged 21 to 43, weighing between 119 and 232 pounds, according to a press release statement.
Participants consumed alcohol to reach blood alcohol concentrations between 0.07% and 0.11%, then ingested either unbuzzd or placebo. The study monitored blood alcohol concentration, vital signs and intoxication symptoms.
The trial found that unbuzzd reduced blood alcohol concentration at a rate more than 40% faster within the first 30 minutes compared to placebo for most participants. The results were statistically significant for both males and females.
The positive clinical data comes as Quantum BioPharma trades at $2.24 with a market capitalization of just $8.69 million. The stock has declined 87.8% over the past six months, though InvestingPro analysis suggests the company may be undervalued at current levels based on its Fair Value assessment.
Study participants reported improved alertness within 30 minutes of consuming unbuzzd. The supplement also stabilized heart rate and blood pressure changes associated with alcohol intoxication, with results noted as statistically significant.
Participants reported a 67% reduction in headache severity at four hours after consuming unbuzzd compared to placebo. No adverse side effects were reported among study participants.
"The science and medical communities for centuries have believed there is no way to significantly speed up alcohol metabolism once it is in your bloodstream," said Anthony Durkacz, Founder and Executive Co-Chairman of Quantum BioPharma.
The unbuzzd formula is licensed to Unbuzzd Wellness Inc. and is available at unbuzzd.com and amazon.com. The company notes that consuming unbuzzd after alcohol ingestion does not permit vehicle operation.
Quantum BioPharma retains 19.86% ownership of Unbuzzd Wellness Inc. as of September 30, 2025, and receives 7% royalty payments on sales until reaching $250 million. The company reports earnings in four days on March 27, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.